I. PURPOSE
To establish guidelines for the collaborative management of patients with a diagnosis of chronic obstructive pulmonary disease (COPD) who are not adequately controlled and to define the roles and responsibilities of the collaborating clinical pharmacist and pharmacy resident following this protocol.

II. POLICY
The clinical pharmacist and pharmacy resident, under this protocol, are authorized to initiate therapy, adjust dosages, change medication and authorize refills to the listed medications. All modifications to therapy must follow the detailed protocol and will be documented in the medical record.

III. PROCEDURE
Clinical pharmacist or pharmacy resident may make changes to inhaled bronchodilators, inhaled or systemic corticosteroids, and combination therapy of these inhaled agents (see Appendix).

Under this protocol, the clinical pharmacist or pharmacy resident will have the authority to order labs to assess treatment and to monitor for adverse events from the drug therapy.

Medication Therapy Management NOT covered in protocol:
• Methylxanthines (theophylline), antibiotics, antiviral agents, and oxygen therapy
• Conditions other than COPD
• Frequent infections and/or possible bronchiectasis, frequent exacerbations, acute COPD exacerbations, or post hospital discharge for COPD exacerbations
• Assessment for hypoxemia and hypercapnia
IV. PROTOCOL

COPD Treatment Algorithm

Established diagnosis of COPD

Assess patient for acute exacerbation

Yes

Refer to physician if patient falls outside of this protocol

No

Assess symptoms/establish severity of stable COPD
- Mild
- Moderate
- Severe

Stable COPD: Step-care pharmacologic approach for management

Encourage exercise, healthy lifestyle, and refer for immunization

All patients

Still smoking

Actively engage patient in smoking cessation program.

COPD not stable: follow-up with primary care physician to determine if other pharmacologic treatment is needed (antibiotics, antitussives, antivirals, etc.)
Initial Visit Protocol

The patient’s medical record will be reviewed and the following information will be gathered and discussed during the initial visit using the COPD workup form (Appendix 1):

- Blood pressure and pulse
- Complete medication history regarding COPD therapy, treatments, ER visits, hospitalizations and intubations secondary to COPD within the past year
- Assess COPD symptoms (cough, wheeze, dyspnea) and symptoms with exertion
- Review or order oximetry at SCC, if < 90 refer back to referring or primary provider
- Review or order spirometry at SCC, if not done at diagnosis
- Assess and classify severity of COPD (Appendix 3)
- COPD medications will be initiated, discontinued or adjusted as needed (Appendix 4 and 5)
- Assess social history, work/environmental exposure, and functional status
- Assess and educate inhaler technique and compliance
- Provide patient with patient education
- Follow-up within 1-4 weeks following initial visit

Follow-up Visit Protocol

Follow-up visits will be established between the clinical pharmacist or pharmacy resident. Follow-up appointments will be scheduled approximately every 1-6 months depending on severity of symptoms. The number of follow-up visits will be determined by the clinical pharmacist and pharmacy resident. Appendix 2 will be used to gather information for follow-up visits.

Assess at follow-up:

- Obtain an updated medication history, including both COPD and non-COPD medications
- Frequency of signs and symptoms of COPD
- History of COPD exacerbations
- Pharmacotherapy: effectiveness, adverse effects, compliance
  COPD medications will be initiated, discontinued or adjusted as needed (Appendix 4 and 5)
- Review or order spirometry if there is a substantial increase in symptoms or a complication
- Review inhaler/spacer technique; have patient demonstrate technique

Health Maintenance

- Spirometry should be performed annually on all COPD patients. Spirometry is needed to make a firm diagnosis of COPD and helps stage COPD severity. Can be used to guide treatment steps.
- All patients should receive annual influenza vaccination – influenza vaccines reduce serious illness and death in COPD patients by 50%.
- All patients should receive a Pneumovax vaccination – recommended for patients 65 years and older, and has been shown to reduce community-acquired pneumonia in those under 65 with FEV1 <40% predicted.
- Encourage and assist with smoking cessation in all patients with COPD.
V. DOCUMENTATION

Written by: Susan Shughrie, RPh, BCACP, CDE, Ambulatory Care Clinical Pharmacist, April 2013

Reviewed by: Ann Lindsay, MD, Stanford Coordinated Care April 2013

Approved by: Dr. Alan Glaseroff, Co-Director, Stanford Coordinated Care, April 2013
Dr. Ann Lindsay, Co-Director, Stanford Coordinated Care, April 2013
Dr. Kathan Vollrath, Stanford Coordinated Care, April 2013
Timothy Engberg, VP Stanford Ambulatory Services, May 2013

Original Date: April 2013

Reviewed Dates:

Revised Dates:

This document is intended for use by staff of Stanford Hospital and Clinics. No representations or warranties are made for outside use. Not for outside reproduction or publication without permission.

Direct inquiries to Ann Lindsay, MD 650.736.0682
Stanford Coordinated Care
Stanford, California 94305
COPD HISTORY WORK UP

1. What worries you most about your COPD? ________________________________________________________

2. What do you want to accomplish at the visit? ______________________________________________________

3. Symptoms:
   - Chronic cough with/without sputum? YES / NO  Intermittently  Every day
   - Wheezing? YES / NO  Most days or nights? YES / NO
   - Dyspnea? YES / NO  Worsens over time? YES / NO  Worse on exercise or rest? YES / NO
     Present every day? YES / NO?

4. History of exposure to risk factors:
   - Does anyone smoke in the home (tobacco, other inhaled substances which produce fumes)? YES / NO
   - Do you smoke? YES / NO  If yes, how much per day?  ____________________________________________
     o Are you willing to quit at this time? YES / NO  (If yes, refer to smoking cessation program)
   - Any exposure to occupational, chemicals, or smoke from home cooking and heating fuels? YES / NO

5. Have you ever gone to the emergency department for a COPD exacerbation? YES / NO
   If yes, how many times in the last 6 months? ____________________________________________________

6. Have you ever been hospitalized for COPD? YES / NO  How many times? _____  Intubated? YES / NO

7. How many days of work have you missed in the past 3 months due to COPD? ______________________

8. Are you able to keep up with your friends and family during routine activities? YES / NO

9. Does your coughing or breathing keep you from doing things that you used to do and enjoy? YES / NO

10. Has your exercise capacity decreased over the years more than it has in your peers? YES / NO

11. Have you used any medications that help you breathe better? YES / NO
    Name of medication (inhalers/pills, prescriptions/OTC): ___________________________________________

12. What other medication have you used for COPD? ________________________________________________

___________________________________________________________________________________________
13. Has your COPD medicine caused you any problems? YES / NO
   • If yes, what problems? shakiness nervousness bad taste sore throat cough
     upset stomach fast heartbeat other______________________________
   • Which medication caused this problem? __________________________________________________

14. Are there any other factors that may affect your ability or desire to take your medications as directed?
   __________________________________________________________________________________
   __________________________________________________________________________________
APPENDIX 2

COPD FOLLOW-UP WORK UP

1. Since your last visit:
   - Has your COPD been any worse? YES / NO
   - Any changes in home or work environment? YES / NO
   - Any exacerbations? YES / NO
     - What do you think caused the symptom to get worse? _____________________________
     - What did you do to control the symptom? ________________________________
     - ER visits? YES / NO
     - Hospitalized? YES / NO
     - Intubated? YES / NO
   - Missed work? YES / NO
     If yes, how much? ____________________________________________________________
   - How and when are you taking your COPD medications? ______________________________
     ____________________________________________________________________________
   - Have you missed any doses of your medications? YES / NO
     - If yes, how much?_______________________ How often? ____________________________
     - Why? _______________________________________________________________________
   - Has your COPD medicine been effective in controlling your symptoms? YES / NO
   - Has your COPD medicine caused you any problems? YES / NO
     - If yes, (circle) shakiness nervousness bad taste sore throat cough
       upset stomach fast heartbeat other____________________
     - Which medication caused this problem? __________________________________________

2. If patient is a smoker: Have you continued to stay off cigarettes? YES / NO
   - If not, how many cigarettes per day are you smoking? ______________________________
   - Would you like to quit smoking? YES / NO (If yes, refer to smoking cessation programs)
### APPENDIX 3

**COPD Classification Scheme: Based on clinical features before treatment** *

<table>
<thead>
<tr>
<th>Grade</th>
<th>Symptoms</th>
<th>FEV&lt;sub&gt;1&lt;/sub&gt; (% predicted)</th>
</tr>
</thead>
</table>
| **GOLD 1:** Mild | • No abnormal signs  
• Cough + sputum | • > 80% |
| **GOLD 2:** Moderate | • Breathlessness + wheeze on moderate exertion  
• Cough + sputum  
• Variable abnormal signs (general reduction in breath sounds, presence of wheezes)  
• Hypoxemia may be present | • Between 79% and 50% |
| **GOLD 3:** Severe | • Dyspnea with any exertion or at rest  
• Wheeze and cough often | • Between 30% and 49% |
| **GOLD 4:** Very Severe | • Lung hyperinflation; cyanosis, peripheral edema and polycythemia in advanced disease | • < 30% |

*The presence of one of the features of severity is sufficient to place a patient in that category. An individual should be assigned to the most severe grade in which any feature occurs.*
## APPENDIX 4
Pharmacologic Therapy for Managing COPD

<table>
<thead>
<tr>
<th>GOLD 1: Mild</th>
<th>Recommended First Choice</th>
<th>Alternative Choice</th>
</tr>
</thead>
<tbody>
<tr>
<td>SA anticholinergic prn or SA beta₂-agonist prn</td>
<td>LA anticholinergic or LA beta₂-agonist or SA beta₂-agonist and SA anticholinergic</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GOLD 2: Moderate</th>
<th>LA anticholinergic or LA beta₂-agonist</th>
<th>LA anticholinergic and LA beta₂-agonist</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>GOLD 3: Severe</th>
<th>ICS + LA beta₂-agonist or LA anticholinergic</th>
<th>LA anticholinergic and LA beta₂-agonist or LA anticholinergic and PDE-4 inhibitor or LA beta₂-agonist and PDE-4 inhibitor</th>
</tr>
</thead>
</table>

| GOLD 4: Very Severe | ICS + LA beta₂-agonist and / or LA anticholinergic | ICS + LA beta₂-agonist and LA anticholinergic or ICS + LA beta₂-agonist and PDE-4 inhibitor or LA anticholinergic and LA beta₂-agonist or LA anticholinergic and PDE-4 inhibitor |

Adapted from the GOLD report 2013 (www.goldcopd.org)
## APPENDIX 5

**Comparative Daily Dosages of Inhaled Corticosteroids for Adults**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Low Dose</th>
<th>Medium Dose</th>
<th>High Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclomethasone HFA (QVAR)</td>
<td>80-240 mcg</td>
<td>&gt;240-480 mcg</td>
<td>&gt;480 mcg</td>
</tr>
<tr>
<td>40 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Budesonide DPI (Pulmicort)</td>
<td>180-600 mcg</td>
<td>&gt;600-1200 mcg</td>
<td>&gt;1200 mcg</td>
</tr>
<tr>
<td>90 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluticasone HFA (Flovent HFA)</td>
<td>88-264 mcg</td>
<td></td>
<td>&gt;440 mcg</td>
</tr>
<tr>
<td>DPI (Flovent Diskus)</td>
<td>200 mcg</td>
<td></td>
<td>1000 mcg</td>
</tr>
<tr>
<td>50 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>220 mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mometasone DPI</td>
<td>220 mcg</td>
<td>440 mcg</td>
<td>&gt;440 mcg</td>
</tr>
<tr>
<td>220mcg/puff</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination Product: Fluticasone/Salmeterol DPI (Advair)</td>
<td>100/50 mcg</td>
<td>250/50 mcg</td>
<td>500/50 mcg</td>
</tr>
<tr>
<td>Budesonide/Formoterol (Symbicort Turbuhaler)</td>
<td>160/9 mcg</td>
<td>&gt;160/9 – 320/18 mcg</td>
<td>320/18 mcg</td>
</tr>
</tbody>
</table>

### Notes:
- The most important determinant of appropriate dosing is the clinical pharmacist’s and pharmacy resident’s judgment of the patient’s response to therapy.
- The clinical pharmacist and pharmacy resident will monitor the patient’s response on several clinical parameters and adjust the dose accordingly.
- The stepwise approach to therapy emphasizes that once control of COPD is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effect.